Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Mangoceuticals, Inc. ( (MGRX) ).
On March 24, 2025, Mangoceuticals, Inc. entered into an agreement with Navy Wharf for exclusive licensing rights to a nutraceutical product. However, on July 30, 2025, both parties agreed to terminate the agreement without incurring material penalties, and Navy Wharf canceled all previously issued shares. Additionally, on July 29, 2025, a warrant holder exercised options to purchase 198,000 shares of common stock, raising $297,000.
More about Mangoceuticals, Inc.
Mangoceuticals, Inc. operates in the nutraceutical industry, focusing on products designed to manage blood glucose and Hemoglobin A1c levels, marketed under the brand Diabetinol® in the United States and Canada.
Average Trading Volume: 170,733
Technical Sentiment Signal: Sell
Current Market Cap: $18.2M
Find detailed analytics on MGRX stock on TipRanks’ Stock Analysis page.